EN | RU
EN | RU

Help Support

Back

Erenumab's efficacy and safety for migraine in real-world use

Migraine Migraine
Migraine Migraine

What's new?

Erenumab, an anti-CGRP receptor monoclonal antibody is a proven, effective, and safe option for migraine management in real-world clinical settings.

A novel systematic review provided robust evidence supporting the effectiveness and safety of Erenumab in real-world settings. This marks the first meta-analysis focusing on the real-world application of Erenumab, highlighting its potential as a reliable therapeutic option for migraine

Jaime Fernández-Bravo-Rodrigo et al. aimed to evaluate the efficacy and safety of Erenumab in decreasing the intensity and incidence of migraines in real-world scenarios. To look for relevant studies on the impact of Erenumab, a database search of Scopus, Web of Science, PubMed and Cochrane up to December 2023 was performed.

The meta-analysis included 53 studies, revealing significant reductions across multiple parameters at the 3-month mark:

  • Monthly Migraine Days: -7.18 days
  • Monthly Headache Days: -6.89 days
  • Headache Impact Test (HIT-6): -6.97
  • Number of Days on Medication: -6.22 days
  • Acute Monthly Intake: -15.75
  • Pain: -1.71

Also, the benefits of Erenumab grew slightly over 6- and 12-month periods. Response rates revealed that about one-third of patients experienced a greater than 30% reduction in MMD/MHD, one-sixth had over 50%, and 3-4% of patients achieved a 100% response rate. The rates of adverse events were logged as 0.34 at 6 months and 0.43 at 12 months.

Source:

European Journal of Pharmacology

Article:

Real-world effectiveness and safety of Erenumab for the treatment of migraine: A systematic review and meta-analysis

Authors:

Jaime Fernández-Bravo-Rodrigo et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: